grey market retatrutide forum Vial of unapproved peptide had double the strength indicated on label Retatrutide and the Grey Market:

Pendulum does not cause injection site reactions because it is oral, which eliminates an entire category of side effects that affect users of GLP-1 injection therapies

The success of dual agonists paved the way for triple GIP/GLP-1/glucagon agonists

That means if you are reading this right now, retatrutide is likely 18 to 24 months away from being something you can actually obtain with a prescription

[1] [3] This is particularly relevant for post-bariatric patients, who may already have altered biliary physiology

One dermatology study found women developed telogen effluvium even when they had lost proportionally less weight than men

In: StatPearls